If this message does not appear correctly, click this link


Tumor Mutational Burden (TMB): Will It Be a Home Run?

By Dr. Song Ling Poon, Medical Science Liaison of ACT Genomics

Immunotherapies are the stars of today and continue to have more advancements on the horizon, especially the development of immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 and CTLA-4. Nevertheless, the objective response rate of either PD-1 or PD-L1 inhibitors across different cancer types, unfortunately, ranges between 10 and 20%. Tumor mutational burden, TMB, has emerged as an important biomarker for predicting ICI response. What are the challenges currently faced by TMB and what is being done to address these issues? Continue Reading



New Panel Launched!


ACTBRCA HRD™ is a new panel designed to evaluate whether a patient is likely to benefit from PARP inhibitors. ACTBRCA HRD™ sequences 48 genes to detect mutations in BRCA1/2 and other homologous recombination repair (HRR) genes. In addition to germline BRCA mutations covered by common BRCA tests, ACTBRCA HRD™ provides more comprehensive information by also detecting BRCA germline large genomic rearrangement (LGR), BRCA somatic mutations in tumor samples, and other HRR-related mutations, allowing physicians to identify more patients suitable for PARP inhibitors. More Info on ACTBRCA HRD™



Singapore Office Has Moved To A New Location!

We are excited to announce that Singapore team has moved to Jit Poh Building in downtown Tanjong Pagar! We were honored to have Mr Jerry Chen, Director of Economic Division and Ms. Holly Chang, Assistant Director of Economic Division from Taipei Representative Office in Singapore to join us during the opening event. Thank you for everyone’s support through the years and we look forward to a great start in this new location.



Combination of Dabrafenib and Trametinib Shows Clinical Benefit in Patients with BRAF-Mutant Biliary Tract Cancer

In the phase 2 basket ROAR study, patients with BRAF V600E mutation in 9 rare tumor types were enrolled and received dabrafenib plus trametinib as second- or later-line treatment. The results of biliary tract cancer cohort were recently published on ASCO Gastrointestinal Cancers Symposium 2019. Of the 557 prescreened biliary tract cancer patients, 49 harbored BRAF V600E mutation and 35 were enrolled. Continue Reading...



Trastuzumab, capecitabine, oxaliplatin and pembrolizumab as first-line treatment demonstrates encouraging activity in HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma

Trastuzumab plus chemotherapy is currently the standard first-line regimen for HER2 positive metastatic gastric or gastroesophageal junction adenocarcinoma. However, trastuzumab induces the expression of PD-L1 on tumor cells and may therefore cause the resistance to trastuzumab. A phase II trial was conducted to examine the efficacy of trastuzumab, chemotherapy plus pembrolizumab in HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma. Continue Reading...



Please do not reply to this email as it is sent from a non-monitored account. To contact us, please email service@actgenomics.com.

  To unsubscribe, please enter your E-Mail :